Sovaldi and Olysio cured 94 percent of people who had genotype 1 of hepatitis C and advanced liver disease in a recent trial.

Faldaprevir and deleobuvir plus Presidio’s PPI-668 cured 92 percent of those with genotype 1a of hepatitis C virus when given with riba...

Eight weeks of the fixed-dose combination tablet of Sovaldi and ledipasvir can cure over 90 percent of non-cirrhotic people with genotype 1 of...

In a large trial, AbbVies ’3-D’ combination therapy cured 92 percent to 96 percent of cirrhotic study participants with geno 1 of hep C.

Gilead Sciences’ fixed-dose combination pill of Sovaldi and ledipasvir cured 94 percent to 99 percent of those with genotype 1 of hepat...

European Union citizens die as a result of viral hepatitis at a rate about 10 times greater than deaths related to HIV.

A fixed-dose combo pill of Sovaldi and ledipasvir is poised to boast a 100 percent success rate in curing hepatitis C among those coinfected w...

The AbbVie ’3-D’ regimen cured 96 percent of people who had genotype 1 of hepatitis C and did not have cirrhosis.

BMS?s daclatasvir and asunaprevir cured between 82 to 90 percent of people with genotype 1b of hepatitis C.

Sovaldi and GS-5816 cured about 95 percent of treatment-naive people with genotypes 1 through 6 of hepatitis C who did not have cirrhosis in a...